|
|
|
|
FOR IMMEDIATE RELEASE
Multicase Inc has received NIH SBIR Phase I award.The Beginning of the Mutagenicity Data Sharing ProjectApril 1st, 2001. The research team of Multicase Inc. has been awarded a Small Business Innovation Research (SBIR) grant from NIH to develop a superior tool to predict the Mutagenic Potential of New Pharmaceuticals in conjunction with the Center for Drug Evaluation and Research (CDER) office of the FDA. The goal of this research proposal is to continue the improvement of predicting mutagenicity by a new methodology. This new treatment entails using several databases concurrently to establish the activity of new compounds. The databases will be developed using NTP information for each strain independently. In other words, we will develop a new database for each of the TA-type Salmonella strains. Based on the available experimental data, we intend develop databases for 8 different Salmonella strains: TA100, TA1535, TA1537, TA97, TA98, TA102, TA104 and TA1538. In addition, we will further divide the data based on whether the induced by S9. Again, based on the available data, we will make three databases for each strain listed above: NA (not activated by S9), HLI (Hamster liver induced by S9), and RLI (rat liver induced by S9). Based on these divisions, we wish to develop a total of 24 databases for the sole purpose of developing an improved model for predicting mutagenicity. For the Phase I Fasttrack section of this proposal, we intend on developing four to six of these modules in the time allocated for the award. Another goal of this work is to maintain a method for ranking the mutagenicity of new compounds. The method we will use for this quantitative value is based on describing the fold-increase of the number of revertants per nanomole (nr/nmol). For each mutagenic compound, a ratio will be calculated based on the maximum nr/nmol value published in literature and the control value. In this model, the highest ratio value will be the most mutagenic compound in the database. Using this protocol, we should be able to predict which compounds are the most mutagenic for each Salmonella strain and extrapolate an overall level of mutagenicity for the complex.
For More Information Contact: |
|
Send mail to
saiakhov@multicase.com with
questions or comments about this web site.
|
